- With an efficacy of 91.6%, as published in the Lancet Medical Journal, the Russian Direct Investment Fund (RDIF) has signed a deal to produce 750 million doses of Sputnik V in India.
- The Health Ministry said that as part of its policy to augment the domestic production of the Covid-19 vaccine, it has proactively encouraged Public Sector Undertakings (PSUs) and private companies to enter into technology transfer agreements with Indian vaccine manufacturers.
- Sputnik V was given emergency use authorization (EUA) by the Drugs Controller General of India (DCGI) in April and was first approved in Russia last year.
Read the original story here.
Sign in or become a tippinsights member to join the conversation.
Just enter your email below to get a log in link.